Point-Counterpoint: HBOT: Is It Worthwhile For DFUs?
- Volume 27 - Issue 3 - March 2014
- 4888 reads
- 0 comments
Five trials, including four RCTs, provided data on minor amputations distal to the ankle joint with outcome assessment for up to 55 months. Pooled analysis of these data resulted in a relative risk of 1.24, revealing identical minor amputation rates between HBOT and conventional therapy, and no evidence to suggest statistical heterogeneity.7 Pooling analysis revealed that, in comparison to treatment without HBOT, adjunctive treatment with HBOT resulted in a signiﬁcantly higher proportion of healed diabetic ulcers. The analysis also revealed that treatment with HBOT was associated with a signiﬁcant reduction in the risk of major amputations but had no effect on the rate of minor amputations. The authors concluded that treatment with HBOT improved the rate of healing and reduced the risk of major amputations in patients with diabetic foot ulcers.
After evaluating the medical literature supporting HBOT as an adjunctive treatment for diabetic foot wounds, I can conclude that additional research is needed to define the specific indications and benefits of this treatment modality. Unfortunately, the literature on the efﬁcacy of HBOT is still not clear. There have been no studies of the effectiveness of this therapy. The importance of effectiveness studies on therapies for the treatment of diabetic foot ulcers is critical.
Therapies such as skin substitutes, acellular dermal matrices and offloading modalities have had extensive study with a high level of well-designed studies. The true RCT that compared HBOT treatment with a sham showed positive results at one year. The two meta-analyses still showed conflicting results. Therefore, long-term studies with the sham control are still needed to show the effectiveness of HBOT.
Dr. La Fontaine is the Associate Professor of the Department of Plastic Surgery at the University of Texas Southwestern Medical Center in Dallas. He is a Fellow of the American College of Foot and Ankle Surgeons, and the American Society of Podiatric Surgeons.
1. Camporesi EM (editor). Hyperbaric Oxygen Therapy Committee Report. Undersea and Hyperbaric Medical Society, Kensington, MD, 1996.
2. Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. Diabetes Care. 1996;19(12):1338-1343.
3. Baroni G, Porro T, Faglia E, et al. Hyperbaric oxygen in diabetic gangrene treatment. Diabetes Care. 1987;10(1):81-86.
4. Oriani G, Meazza D, Favales F, et al. Hyperbaric oxygen therapy in diabetic gangrene. J Hyperb Med. 1990;5(3):171-175.
5. Oriani G, Michael M, Meazza D, et al. Diabetic foot and hyperbaric oxygen therapy: a ten-year experience. J Hyperb Med. 1992;7(3):213-221.
6. Wattel F, Mathieu D, Coget JM, Billard V. Hyperbaric oxygen therapy in chronic vascular wound management. Angiology. 1990;41(1):59-65.
7. Liu R, Li L, Yang M, Boden G, Yang G. Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers. Mayo Clin Proc. 2013;88(2):166-175.
8. Löndahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care. 2010 May;33(5):998-1003.
9. Kranke P, Bennett MH, Martyn-St James M, Debus SE. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2012 10.1002/14651858. CD004123.pub3.
10. Margolis DJ, Gupta J, Hoffstad O, Papdpopoulus M, Glick HA, Thom SR, Mitra N. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation. Diabetes Care. 2013; 36(7):1961–1966.